mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Moderna and Merck revealed on Wednesday the promising results of their joint mRNA-based vaccine in a Phase 3 melanoma clinical trial. The personalized vaccine, intended to target each patient's unique cancer mutations, demonstrated effectiveness against melanoma, a deadly skin cancer. Although the announcement provided limited details, a potential success in both mRNA vaccines and targeted cancer treatments is anticipated.
The Phase 3 trial involved 1,137 patients with stage IIB–IV melanoma, who had undergone surgical removal before participating in the trial. The patients were split into two groups, with a two-to-one ratio, and received either the tailored mRNA vaccine (intismeran or mRNA-4157) combined with Merck's existing monoclonal antibody treatment Keytruda, or Keytruda alone.
The trial was controlled and double-blind, ensuring neither the medical team nor the participants knew who received which treatment. Both patient groups underwent treatment for approximately a year.
Written by urgent.news from Ars Technica's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial medicalxpress.com
- mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say arstechnica.com
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial iol.co.za
- Merck, Moderna claim ‘promising’ skin cancer vaccine results in key trial torontosun.com
- Moderna shares double as cancer vaccine data rekindles investor hopes investing.com
- Moderna shares double as cancer vaccine data rekindles investor hopes finance.yahoo.com
